In this study, it was found that the proportions of CD3+ and CD4+/CD8+ in the observation group were higher than those in the control group after treatment, and the CD8+ was lower, indicating that Dex combined with isoniazid could regulate the peripheral blood T cell subsets of patients with TBM and improve the immune function. The gene discussed is CD8A; the disease is meningeal tuberculosis.